Deals Of The Week: Valeant/Eyetech, Merck/Supera Farma, Merck/Zhifei
Biogen’s purchase of Stromedix completes the buy-up of independently held biotech assets in the furious competition to take the lead in idiopathic pulmonary fibrosis.
You may also be interested in...
Started by a former Biogen executive, Stromedix licensed STX-100 from Biogen and developed it into an attractive candidate in an area the reshaped big biotech wants to pursue.
Talk to any big pharma business development executive about dealmaking trends for more than 15 minutes and the word out-licensing is bound to crop up. But are major drugmakers moving beyond the rhetoric and actually giving up rights to individual assets that heretofore would have been deemed too valuable to merit out-licensing? An analysis by IN VIVO suggests yes – but with qualifications.
Pfizer demonstrates its "balanced portfolio" approach, with five recent deals, but concerns linger about its ability to meet its 2012 financial targets .